Patents by Inventor Craig A. Strathdee

Craig A. Strathdee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5681942
    Abstract: Fanconi Anemia is a human genetic disease, the precise cause of which is, to date, unknown. This invention provides an isolated human cDNA molecule which is able to specifically complement, in one type of Fanconi Anemia, (type C) the characteristic defect exhibited by cells derived from patients with Fanconi Anemia. The genomic gene from which this cDNA is derived is also provided as is the sequence of the protein encoded by this gene. Mutations in this gene are proposed to underlie Fanconi Anemia Type C. Diagnostic and therapeutic applications which derive from this work are described. The murine homolog of the human cDNA is also provided.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: October 28, 1997
    Assignees: HSC Research & Development Limited Partnership, The United Medical And Dental Schools of Guy's and St. Thomas's Hospitals
    Inventors: Manuel Buchwald, Craig A. Strathdee, Rachel Wevrick, Christopher George Porter Mathew
  • Patent number: 5055400
    Abstract: The gene coding for Pasteurella haemolytica leukotoxin can be cloned in a plasmic expressed in Escherichia coli. The leukotoxin gene can be isolated from a clone bank of P. haemolytica. The clone bank is constructed by partial digestion of genomic DNA. The resultant 5 to 10 kilobase-pair fragments are ligated into plasmid vector pBR322. The resultant clones are screened for the production of P. haemolytica soluble antigens by a colony enzyme-linked immunosorbent assay blot method with a rabbit antiserum raised against the soluble antigens. The clones producing P. haemolytica soluble antigens are then analyzed for the production of the leukotoxin by a cytotoxicity assay with cells from a bovine leukemia-derived B-lymphocyte cell line as the target cells. Positive clones are identified, and subsequent restriction analysis of the recombinant plasmids shows the same insert DNA is cloned in the plasmid vector. The DNA sequence analysis of the insert DNA reveals regions coding for the leukotoxin.
    Type: Grant
    Filed: November 26, 1986
    Date of Patent: October 8, 1991
    Assignee: University of Guelph
    Inventors: Reggie Y. C. Lo, Patricia E. Shewen, Craig A. Strathdee